Abstract:Clostridioides difficile (C. difficile) infection (CDI) is the most common hospital-acquired infection. With the combination of a high rate of antibiotic resistance and recurrence, it has proven to be a debilitating public health threat. Current treatments for CDI include antibiotics and fecal microbiota transplantation, which contribute to recurrent CDIs and potential risks. Therefore, there is an ongoing need to develop new preventative treatment strategies for CDI. Notably, gut microbiota dysbiosis is the primary risk factor for CDI and provides a promising target for developing novel CDI therapy approaches. Along with gut microbiota dysbiosis, a reduction in important gut metabolites like secondary bile acids and short-chain fatty acids (SCFAs) were also seen in patients suffering from CDI. In this review study, we investigated the roles and mechanisms of gut microbiota and gut microbiota-derived gut metabolites, especially secondary bile acids and SCFAs in CDI pathogenesis. Moreover, specific signatures of gut microbiota and gut metabolites, as well as different factors that can modulate the gut microbiota, were also discussed, indicating that gut microbiota modulators like probiotics and prebiotics can be a potential therapeutic strategy for CDI as they can help restore gut microbiota and produce gut metabolites necessary for a healthy gut. The understanding of the associations between gut microbiota–gut metabolites and CDI will allow for developing precise and sustainable approaches, distinct from antibiotics and fecal transplant, for mitigating CDI and other gut microbiota dysbiosis-related diseases.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the treatment and prevention of **Clostridioides difficile infection (CDI)**. Specifically, the paper focuses on the following aspects: 1. **Antibiotic resistance and recurrence problems**: The current main treatment methods for CDI are the use of antibiotics (such as vancomycin and fidaxomicin), but these methods are prone to lead to antibiotic resistance and recurrent infections, posing a serious threat to public health. 2. **Dysbiosis of the gut microbiota**: The imbalance of the gut microbiota is one of the main risk factors for CDI. The use of antibiotics, proton - pump inhibitors and other drugs can change the composition of the gut microbiota and increase the risk of CDI. 3. **Limitations of existing treatment methods**: Although fecal microbiota transplantation (FMT) is effective in some cases, it has potential risks, such as the spread of pathogens. Therefore, new, safer and more effective treatment strategies need to be developed. 4. **Mechanisms of action of gut metabolites**: The paper explores the mechanisms of action of the gut microbiota and its - derived metabolites (such as secondary bile acids and short - chain fatty acids) in the pathological process of CDI. These metabolites can inhibit the growth and spore germination of Clostridioides difficile through multiple pathways, thus providing protection against CDI. 5. **Exploration of new treatment strategies**: Based on the above research, the paper proposes to restore gut health by regulating the gut microbiota (such as using probiotics, prebiotics, etc.), produce necessary metabolites, and thus provide a precise and sustainable treatment plan for CDI. ### Specific problem summary - **High recurrence rate**: Approximately 20% - 35% of patients will develop recurrent CDI after the initial infection, and 40% - 60% of them may experience a second recurrence. - **Antibiotic resistance**: The resistance of Clostridioides difficile to antibiotics is increasing continuously, especially during the epidemic due to the overuse of antibiotics. - **Insufficiency of existing treatment methods**: Although antibiotics and FMT have certain effects, they have problems such as unstable efficacy and potential risks. ### Solutions - **Understand the relationship between the gut microbiota and metabolites**: By studying the interaction between the gut microbiota and metabolites, find new targets that can predict and intervene in CDI. - **Develop new treatment strategies**: Use probiotics, prebiotics, etc. to regulate the gut microbiota, restore a healthy gut environment, and reduce the occurrence and recurrence of CDI. Through these studies, the paper aims to provide new ideas and methods for the prevention and treatment of CDI, especially to find precise and sustainable treatment strategies different from traditional antibiotics and FMT.

Gut Microbiota–Gut Metabolites and Clostridioides difficile Infection: Approaching Sustainable Solutions for Therapy

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies

Probiotics: insights and new opportunities for Clostridioides difficile intervention

Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface

Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections

The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection

Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment

Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile

Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics

Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review

Advances in Therapeutic Strategies for the Management of Clostridioides difficile Infection

Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection

Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review

Modulation of Lactobacillus Rhamnosus GG on the Gut Microbiota and Metabolism in Mice with Clostridioides Difficile Infection

Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies

Microbial ecology between Clostridioides difficile and gut microbiota

Disordered Intestinal Microbial Communities During Clostridioides difficile Colonization and Subsequent Infection of Hepatic Cirrhosis Patients in a Tertiary Care Hospital in China

The Evaluation of Fecal Microbiota Transplantation Vs Vancomycin in a Clostridioides Difficile Infection Model.

Post-infectious ibs following Clostridioides difficile infection; role of microbiota and implications for treatment

Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population

New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation